The health-care reform bill continues to improve
Andrew Pollack reports that the White House wants a shorter period of patent exclusivity for biologics -- which is very, very good news.
Both the House and Senate bills would provide a brand-name biologic drug with 12 years of protection from competition, even if the drug’s patents expire before that.
Until now it looked like the matter was settled because the 12-year period got wide bipartisan support in both chambers. And with Congress having much more prominent issues to grapple with, there seemed little chance this issue would be reopened.
That has changed. Mr. Obama apparently met with Congressional leaders and specified a shorter exclusivity period as one of the changes he wanted in the legislation, according to James Greenwood, the president of the Biotechnology Industry Organization, the biotech trade group, which favors the 12-year period.
For a good look at the whole issue, read this article. But the quick version is that there's serious money in generic competition for biologics: $378 billion over two decades, according to one analysis. I've heard the White House is likely to push for a 10-year exclusivity window, which isn't a revolutionary change, but it's better. And it's part of the continuing surprise that is the final days of health-care reform: The bill seems to be getting better, not worse, as it nears the finish line.
Posted by: mahye1935 | January 15, 2010 5:59 PM | Report abuse
Posted by: zeppelin003 | January 15, 2010 6:08 PM | Report abuse
Posted by: bmull | January 15, 2010 6:57 PM | Report abuse
Posted by: HalHorvath | January 15, 2010 7:01 PM | Report abuse
Posted by: ethelmertz | January 15, 2010 7:24 PM | Report abuse
Posted by: zosima | January 18, 2010 2:19 AM | Report abuse
Posted by: truck1 | January 18, 2010 8:20 AM | Report abuse
Posted by: cruisedoc | January 20, 2010 12:21 AM | Report abuse
The comments to this entry are closed.